Method of biomarker testing for autism spectrum disorder for early intervention

Unmet Need: Early individualized intervention for autism spectrum disorder in children

Autism spectrum disorder (ASD) is increasingly common in the United States, affecting children of various racial, ethnic, and socioeconomic groups. Current interventions for ASD largely use applied behavior analysis (ABA). However, this can be costly, restrictive, and involves a later mean age for diagnosis. Improving methods that can provide earlier intervention for ASD would have a great impact on proper, timely, and individualized intervention, outcomes, and pathogenesis.

The Technology: Biomarkers for early identification and intervention for autism spectrum disorder

This technology describes biomarkers that can be found in plasma for early identification of children at risk for autism spectrum disorder (ASD). Specifically, this involves using metabolomic analyses for profiling and identification of dysregulated pathways. Consequently, this technology can be used to determine early biomarkers for early diagnosis and intervention of ASD to improve outcomes. The metabolomic profiles that may be used and associated with ASD could potentially enable intervention as early as birth.

Applications:

Diagnostic assay for autism spectrum disorder
Research tool for studying metabolic and metabolomic profiles associated with autism spectrum disorder
Tool for raising awareness and intervention for autism spectrum disorder
Research tool for integrating metabolomics for pathogenesis and biomarkers of autism spectrum disorder

Advantages:

Early diagnosis of autism spectrum disorder
Early intervention of autism spectrum disorder
Individualized profiling and patient-based intervention
Cost-effective
Supplemental diagnostic assay and profiling tool

Lead Inventor:

Walter Ian Lipkin, MD

Patent Information:

Patent Pending

Related Publications:

Che X, Roy A, Bresnahan M, Mjaaland S, Reichborn-Kjennerud T, Magnus P, Stoltenberg C, Shang Y, Zhang K, Susser E, Fiehn O, Lipkin WI. “Metabolomic analysis of maternal mid-gestation plasma and cord blood in autism spectrum disorders” Mol Psychiatry. 2023 Apr 10; 28: 2355-2369.

Tech Ventures Reference:

IR CU23349
Licensing Contact: Kristin Neuman